Oncology Institute, Inc. (NASDAQ: DFPH)

Oncology Institute, Inc., or TOI, is a prominent player in the healthcare industry, specifically in the field of oncology. The company is known for its value-based approach, which aims to deliver better patient outcomes at a lower cost. This approach differentiates TOI from its competitors, making it a leading entity in the sector.

TOI's primary business activities revolve around managing community-based oncology practices across 15 markets and five states in the United States. The company provides a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, and innovative programs such as outpatient blood product transfusions. TOI's model is designed to provide high-quality and lower-cost care delivery through various capabilities, such as recruiting processes focused on selecting physicians who want to practice evidence-based medicine, technology-enabled care pathways ensuring adherence to evidence-based clinical protocols, strong clinical culture and physician oversight, care management to prevent unnecessary hospitalizations, and clinically appropriate integration of palliative care and hospice aligned with patients' goals of care.

The company generates revenue through its managed clinics, which are staffed with 130 oncologists and advanced practice providers. TOI's primary products and services include medical oncology services, clinical trials, and research. The customer base consists of patients covered by value-based contracts, including Medicare Advantage, Medicaid, and commercial patients.

In the realm of competition, TOI faces challenges from large and medium-sized local and national providers of cancer care services. However, the company's value-based care model and focus on delivering better patient outcomes at a lower cost set it apart from its competitors. TOI's closest competitors are traditional oncology physician practices, such as American Oncology Network, Inc., Florida Cancer Specialists & Research Institute, LLC, U.S. Oncology Network, Inc., and OneOncology, Inc. These organizations are predominantly reimbursed via FFS contracts, which can often lead to overutilization of treatments that may be medically appropriate but result in higher costs.

TOI's growth strategy involves expanding its footprint in existing markets, entering new markets, and exploring opportunities for mergers and acquisitions. The company has established relationships with major payors, including Anthem, CareMore Health, Heritage Provider Network, and Optum Care.

TOI's key offerings include medical oncology services, clinical trials, and research. The medical oncology services encompass physician services, in-house infusion and dispensary, radiation, and innovative programs such as outpatient blood product transfusions. These services are designed to provide high-quality and lower-cost care delivery.

TOI's value-based care model is a critical aspect of its business. This model is designed to deliver better patient outcomes at a lower cost. The affiliated providers focus on NCCN guideline adherence and, when possible, choose clinically equivalent but lower-cost therapeutics. This approach differentiates TOI from traditional oncology practices, which often prioritize volume over value.